HEMOPHILIA A AND B
-
Community awaits decisions on access to Hemlibra
Montreal, February 4, 2021 – The hemophilia community is awaiting decisions by Canadian health authorities on access to Hemlibra for people with hemophilia A without...
-
Results from a CHS/Novo Nordisk Psychosocial Research Program project now published
In 2018, Jennifer King, social worker at the Saskatchewan Health Authority in Saskatoon, was awarded a grant through the CHS/Novo Nordisk Psychosocial Research Program for...
-
FAQs – COVID-19 vaccine and bleeding disorders
The Association of Hemophilia Clinic Directors of Canada (AHCDC) has issued a message to address the most frequent questions asked with regards to the COVID-19...
-
COVID-19 vaccination guidance for people with bleeding disorders
CLICK HERE to read the joint guidance notice from the World Federation of Hemophilia (WFH), European Association for Haemophilia and Allied Disorders (EAHAD), European Haemophilia Consortium...
-
Announcement of a clinical trial for Vioxx for people with hemophilia
(…) The pain drug became synonymous with pharmaceutical risk more than 15 years ago when studies revealed that it roughly doubled patients’ risk of heart...